H2O Innovation (OTCMKTS: HEOFF) and Cesca Therapeutics (NASDAQ:KOOL) are both small-cap industrial products companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings.
This table compares H2O Innovation and Cesca Therapeutics’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
This is a summary of recent ratings for H2O Innovation and Cesca Therapeutics, as reported by MarketBeat.com.
||Strong Buy Ratings
H2O Innovation presently has a consensus target price of $2.00, suggesting a potential upside of 143.25%. Given H2O Innovation’s stronger consensus rating and higher probable upside, equities analysts clearly believe H2O Innovation is more favorable than Cesca Therapeutics.
Volatility and Risk
H2O Innovation has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Cesca Therapeutics has a beta of -0.77, meaning that its share price is 177% less volatile than the S&P 500.
Valuation and Earnings
This table compares H2O Innovation and Cesca Therapeutics’ revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
H2O Innovation has higher revenue and earnings than Cesca Therapeutics.
Insider & Institutional Ownership
2.6% of Cesca Therapeutics shares are owned by institutional investors. 3.9% of Cesca Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
H2O Innovation beats Cesca Therapeutics on 9 of the 12 factors compared between the two stocks.
H2O Innovation Company Profile
H2O Innovation Inc. provides integrated water treatment solutions based on membrane filtration technology in Canada, the United States, Spain, China, the United Arab Emirates, Mexico, France, Egypt, and internationally. It designs, manufactures, and markets systems and equipment for the production of drinking water and industrial process water, reclamation and reuse of water, and desalination of seawater and treatment of wastewater. The company also provides products, as well as membrane filtration systems' spare parts, such as pumps, valves, membranes, filters, media, and other replacement parts of water or wastewater treatment system; and specialty chemicals for membrane pre-treatment applications, as well as develops blends for maintenance, preservation, and cleaning of membrane systems. In addition, it offers specialty coagulants for conventional and membrane filtration systems, as well as flocculants; a line of couplings and fittings for industrial and municipal applications; cartridge filter housings, bag filters, strainers, and cartridge filter elements; and maple syrup products and equipment, such as evaporators, reverse osmosis separators, monitoring solutions, membranes, fittings, tubing, tanks, press filters, and other products related to the maple syrup industry. Further, the company provides operation and maintenance services for water and wastewater treatment systems; and public works services, which include street maintenance, drainage maintenance, and solid waste collection, as well as leases containerized water or wastewater treatment systems, and pilot units. It primarily serves municipalities and local governments; communities and private developments; energy and power plants; food and beverages industries; oil and gas markets; mining and workers camps; and other industrial segments. The company was founded in 2000 and is headquartered in Quebec City, Canada. H2O Innovation Inc. is a subsidiary of Amsterdams Effectenkantoor B.V.
Cesca Therapeutics Company Profile
Cesca Therapeutics Inc. is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. The Company focuses on the business of research, development and commercialization of autologous cell-based therapeutics for use in the regenerative medicine industry. The Company’s therapeutic development initiatives focuses on the fields of cardiovascular medicine and orthopedic regeneration. The Company offers a range of products, such as SurgWerks System, CellWerks System, AutoXpress System (AXP), MarrowXpress System (MXP), BioArchive System, and manual bag sets for use in the processing and cryogenic storage of cord blood.
Receive News & Ratings for H2O Innovation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H2O Innovation and related companies with MarketBeat.com's FREE daily email newsletter.